San Francisco, CA – December 12, 2023 – A groundbreaking new study, the WISDOM study, is poised to fundamentally reshape the landscape of breast cancer screening, advocating for a personalized, risk-adapted approach over the long-standing practice of routine annual mammograms for all. Published today in the prestigious journal JAMA and presented concurrently at the San Antonio Breast Cancer Symposium, the research suggests that by aligning screening frequency with a woman’s unique risk profile, healthcare providers can significantly reduce the incidence of advanced cancer diagnoses while optimizing resource allocation and patient care.
This paradigm shift, spearheaded by researchers at the University of California, San Francisco (UCSF) and a consortium of institutions nationwide, moves beyond a one-size-fits-all, age-centric model. Instead, it champions a comprehensive risk evaluation that integrates genetic, biological, and lifestyle factors, offering a more precise and effective path to early detection and prevention.
A Paradigm Shift in Breast Cancer Screening
The core finding of this extensive research is clear: tailoring breast cancer screening to an individual woman’s risk is not only safer but demonstrably more effective than the conventional reliance on standardized, age-based annual mammograms. For decades, clinical guidelines have largely dictated a uniform screening schedule, typically recommending annual or biennial mammograms starting at a certain age for the general population. However, this approach often fails to account for the vast spectrum of risk that exists among women, leading to potential over-screening for some and inadequate screening for others.
The WISDOM study directly challenges this established norm, presenting compelling evidence that a personalized strategy can prevent more advanced cancers from developing or being missed, all while ensuring that individuals receive the appropriate level of surveillance. This precision medicine approach promises to usher in a new era of breast health, moving away from broad generalizations to finely tuned, patient-specific care plans. The study’s implications extend far beyond the clinic, touching on policy, public health, and the very philosophy of preventive medicine.
The Genesis of WISDOM: Challenging Decades-Old Guidelines
The journey to this transformative finding began years ago, rooted in a growing dissatisfaction with the limitations of existing breast cancer screening guidelines. For decades, the medical community largely operated under the assumption that most women faced a relatively similar risk of developing breast cancer, and thus, uniform age-based screening protocols were deemed appropriate. These guidelines, while well-intentioned and historically effective in their time, often prescribed a universal annual mammogram for women over a certain age, typically 40 or 50, irrespective of other contributing factors.
However, scientific understanding of breast cancer risk has evolved dramatically. Research has long underscored that a woman’s susceptibility to the disease is a complex interplay of genetic predispositions, family history, lifestyle choices, breast density, and other health factors, meaning risk can vary wildly from person to person. The inadequacy of an age-alone approach became increasingly evident, leading to concerns about both over-screening (with its associated anxieties, false positives, and unnecessary procedures) and under-screening (missing aggressive cancers in younger or higher-risk individuals).
It was against this backdrop that the WISDOM study (Women Informed to Screen Depending On Measures of Risk) was conceived. Launched in 2016, the study’s primary objective was to directly compare the efficacy and safety of traditional annual mammography with a novel, individualized, risk-based screening strategy. UCSF served as the coordinating center for this ambitious undertaking, bringing together a multidisciplinary team of experts from across the United States.
The initial phase of the WISDOM study involved an impressive cohort of 46,000 women across the United States. These participants were randomized into two arms: one following standard annual screening guidelines and the other adhering to a personalized, risk-based regimen. The findings from this crucial first phase, now published on December 12th in JAMA and highlighted at the San Antonio Breast Cancer Symposium, represent a significant milestone, offering robust data to support a fundamental shift in clinical practice and public health policy.
Unpacking the WISDOM Study: A Deeper Dive into Methodology
The WISDOM study’s methodology represents a sophisticated departure from conventional screening trials. Rather than simply comparing different fixed frequencies of mammography, it employed a dynamic, individualized approach to risk assessment. Researchers utilized well-validated risk models to meticulously categorize participants into four distinct groups, considering a comprehensive array of factors that contribute to breast cancer risk. These factors included:
- Age: While moving beyond age as the sole determinant, it remained a crucial variable in the overall risk calculation.
- Genetic Information: This included assessment for known pathogenic variants like BRCA1 and BRCA2, as well as an innovative approach to evaluating smaller DNA changes through polygenic risk scores.
- Lifestyle Factors: Elements such as diet, physical activity levels, alcohol consumption, and body mass index (BMI) were incorporated.
- Health History: Personal and family history of breast cancer or other related conditions played a significant role.
- Breast Density: Known to be an independent risk factor for breast cancer and a challenge for mammographic detection, breast density was also factored in.
By combining these multifaceted data points, the researchers were able to create a nuanced risk profile for each participant, guiding personalized screening recommendations.
The four risk categories and their tailored screening advisories were as follows:
- Lowest Risk Group (26% of participants): For women identified as having the lowest risk, the study advised delaying routine screening until age 50, or until an advanced algorithm indicated their individual risk had naturally increased to that of a typical 50-year-old woman. This recommendation reflects a strategic move to avoid unnecessary early screenings, reducing potential anxiety, false positives, and cumulative radiation exposure for a substantial portion of the population for whom the benefits of early screening might not outweigh the harms.
- Average Risk Group (62% of participants): The majority of participants fell into the average risk category. For these women, the study recommended biennial screening – undergoing a mammogram every two years. This frequency balances the need for regular surveillance with the recognition that annual screening may not provide significant additional benefit for this group, while still offering timely detection.
- Elevated Risk Group (8% of participants): For women with an elevated risk profile, annual mammograms were recommended. This increased frequency ensures closer monitoring for individuals who, due to a combination of risk factors, have a higher likelihood of developing breast cancer.
- Highest Risk Group (2% of participants): This category represented the most vulnerable population within the study. For these women, the recommendation was for highly intensive screening: twice a year, alternating between mammography and MRI, regardless of age. The inclusion of MRI, a more sensitive imaging modality, for this group underscores the commitment to aggressive early detection for those at greatest risk, where traditional mammography alone might not suffice.
Crucially, the WISDOM study extended its personalized approach beyond just screening frequency. Participants identified as having elevated or highest risk also received customized guidance aimed at lowering their overall chances of developing breast cancer. This proactive prevention strategy included access to an innovative online decision-making tool focused on breast health, providing tailored information and resources. Furthermore, these higher-risk women had direct contact with a dedicated breast health specialist, allowing for individualized counseling and support. Recommendations encompassed actionable lifestyle changes, such as improving dietary habits and increasing physical activity, both of which are known to influence cancer risk. Discussions also included the potential benefits and risks of medications that can help reduce breast cancer risk for certain individuals. This holistic approach emphasizes a continuum of care, from risk assessment to tailored screening to personalized prevention strategies.
Beyond Mammograms: The Crucial Role of Genetic Insight
One of the most profound and potentially practice-changing revelations from the WISDOM study emerged from its comprehensive genetic testing component. Unlike many previous studies that limited genetic screening to women with a strong family history of breast cancer, WISDOM offered genetic testing to all participants, regardless of their familial background. This inclusive approach yielded a startling and significant finding: 30% of women who tested positive for a genetic variant linked to a higher breast cancer risk reported absolutely no family history of the disease.
This discovery has immense implications for current clinical guidelines. Under existing protocols, many of these women – those carrying pathogenic variants like BRCA1 and BRCA2, or other significant genetic markers, but lacking a family history – would typically not qualify for genetic testing. Consequently, their elevated risk would remain undetected, leaving them without the opportunity for intensified screening or preventive interventions. The WISDOM study thus highlights a critical blind spot in conventional screening practices, underscoring the urgent need to broaden access to genetic testing to ensure no high-risk individual is overlooked simply due to the absence of a family history.
Furthermore, the study ventured beyond well-known pathogenic variants, evaluating the cumulative impact of smaller DNA changes that, when combined, can form a polygenic risk score (PRS). This innovative approach significantly improved the precision of risk predictions. By integrating PRSs into the overall risk assessment model, researchers found that 12% to 14% of participants were reassigned to a different risk category. This refinement demonstrates the power of advanced genomic insights in fine-tuning individual risk profiles, leading to even more accurate and personalized screening recommendations.
Allison S. Fiscalini, MPH, of UCSF, director of the Athena Breast Health Network and the WISDOM study, emphasized the significance of this genetic component: "This is one of the first studies to offer genetic testing to all women, regardless of family history. When used as part of a comprehensive risk assessment, these results could have a real impact on improving the safety and effectiveness of screening and prevention." Her statement underscores the potential for genetic testing to become a more routine and integral part of breast cancer risk assessment, moving beyond its current niche application to a broader population benefit.
Evidence of Efficacy and Patient Acceptance
A critical measure of any new screening strategy is its impact on health outcomes. The WISDOM study delivered compelling results on this front: the personalized screening approach did not lead to a higher rate of late-stage cancer diagnoses. This finding is paramount, directly addressing a primary concern that a less frequent screening schedule for lower-risk women might result in missing cancers until they are more advanced and harder to treat. The study’s ability to maintain or improve early detection while tailoring frequency underscores the efficacy and safety of the risk-based model. It suggests that resources are being more effectively deployed, with intensive screening directed precisely to where it is most needed.
Beyond clinical outcomes, patient acceptance is crucial for the successful implementation of any new health strategy. The WISDOM study gathered encouraging data in this regard as well. While some participants were randomized to either the traditional or personalized screening arms, women who chose not to be randomized were able to join an observational group and select their preferred screening strategy. Strikingly, 89% of these women opted for the risk-based screening approach, indicating strong public acceptance and a clear preference for a more individualized method of care. This high rate of voluntary adoption suggests that women are not only open to but actively seek out a screening strategy that aligns more closely with their personal health profile and perceived risk.
Jeffrey A. Tice, MD, a UCSF professor of Medicine and co-author specializing in breast cancer risk assessment tools, articulated the strategic benefits of this approach: "Shifting resources from lower-risk women to higher-risk women is an efficient, effective approach to screening for and preventing breast cancer." His statement highlights the dual advantages of the personalized model: improved effectiveness in targeting high-risk individuals and enhanced efficiency in resource allocation, potentially reducing the burden on healthcare systems while maximizing positive health outcomes. This demonstrates that a personalized approach is not only clinically sound but also economically and logistically viable.
Official Responses and Expert Endorsements
The publication of the WISDOM study’s findings has elicited strong endorsements from lead researchers, signaling a collective belief that this research will serve as a catalyst for transformative change in clinical practice and guidelines.
Laura J. Esserman, MD, MBA, director of the UCSF Breast Care Center and the study’s first author, delivered a powerful statement on the potential impact of their work: "These findings should transform clinical guidelines for breast cancer screening and alter clinical practice." Her unequivocal call for change underscores the profound implications of the study. Dr. Esserman elaborated on the essence of the new paradigm: "The personalized approach begins with risk assessment, incorporating genetic, biological, and lifestyle factors, which can then guide effective prevention strategies." This emphasizes that the study is not merely about adjusting mammogram schedules, but about embedding a comprehensive, individualized risk evaluation at the very foundation of breast cancer prevention and detection.
UCSF, serving as the coordinating center for the WISDOM study, has played a pivotal role in bringing this research to fruition. The institution’s commitment to precision medicine and its long-standing leadership in cancer research have been instrumental in developing and executing a study of this magnitude. The strong endorsement from UCSF’s leadership, particularly Dr. Esserman, reinforces the credibility and potential for widespread adoption of these findings. Their collective voice provides a powerful impetus for national and international health organizations to review and update existing screening protocols, moving away from generalized advice towards more nuanced, evidence-based recommendations tailored to each woman’s unique risk landscape. This shift promises to empower both patients and clinicians with more accurate information, leading to more informed decisions about breast cancer screening and prevention.
Implications for the Future of Breast Cancer Care
The WISDOM study’s findings carry profound implications that are set to ripple across various facets of healthcare, from individual patient care to national health policies.
1. Clinical Practice Transformation: For clinicians, the study signals a move away from prescriptive, age-based recommendations to a more consultative and data-driven approach. Doctors will need to integrate comprehensive risk assessment tools into their practices, engaging patients in detailed discussions about their genetic background, lifestyle, and health history. This shift demands a higher level of personalized counseling, empowering patients to understand their specific risk profile and participate actively in their screening decisions. It also suggests that genetic testing, currently often reserved for those with strong family histories, may become a more routine component of initial breast health evaluations for a broader population.
2. Policy and Guideline Revision: Major health organizations, such as the American Cancer Society (ACS), the U.S. Preventive Services Task Force (USPSTF), and others globally, will face increasing pressure to review and revise their breast cancer screening guidelines. The WISDOM study provides compelling evidence to support the integration of individualized risk assessment into these recommendations. This could lead to a departure from blanket age-based starting points and frequencies, replaced by more nuanced algorithms that factor in a wider array of risk elements. Such policy changes would likely influence insurance coverage, ensuring that personalized screening and preventive measures are accessible and affordable for all women.
3. Enhanced Public Health Outcomes: By reallocating resources more efficiently, the personalized approach holds the potential for significant public health benefits. Lower-risk women could avoid unnecessary anxiety, false positives, and the potential harms of over-screening (e.g., radiation exposure, unnecessary biopsies). Conversely, higher-risk women would receive more intensive, potentially life-saving screening and targeted prevention strategies, leading to earlier detection of aggressive cancers and improved survival rates. This optimized resource utilization could ultimately lead to a reduction in the overall burden of advanced breast cancer within the population.
4. Advancements in Research and Development: The WISDOM study itself is a testament to the power of ongoing research, and its successor, WISDOM 2.0, is already underway. This continuous refinement of risk assessment models will drive further innovation in understanding breast cancer etiology and developing even more precise diagnostic and preventive tools. The focus on identifying women at higher likelihood of developing aggressive breast cancers highlights a critical area for future research, aiming to intervene even more effectively.
5. Patient Empowerment and Education: A personalized approach inherently empowers patients. As women become more aware of their individual risk factors through comprehensive assessments, they can engage more meaningfully with their healthcare providers. This necessitates increased public education campaigns to help women understand the nuances of risk, the benefits and limitations of different screening modalities, and the importance of lifestyle interventions in cancer prevention. The study’s finding of high patient acceptance for risk-based screening suggests a public readiness for this shift.
The WISDOM study represents a significant leap forward in the journey towards precision medicine in oncology. By demonstrating the superior efficacy and safety of individualized risk-based screening, it lays the groundwork for a future where breast cancer detection and prevention are not just more effective, but also more patient-centric and resource-efficient.
Looking Ahead: WISDOM 2.0 and Beyond
The groundbreaking findings from the initial phase of the WISDOM study are not the culmination of this ambitious research but rather a powerful springboard for its continued evolution. Researchers are already forging ahead with the WISDOM 2.0 study, which is actively enrolling participants, building upon the foundational insights gained.
The primary goal of WISDOM 2.0 is to further refine the risk assessment methodologies, aiming for an even more granular understanding of individual susceptibility to breast cancer. This next phase seeks to better identify women who face a higher likelihood of developing aggressive forms of breast cancer, which are often more challenging to treat and have poorer prognoses if not caught early. By honing these identification tools, the study intends to provide these at-risk individuals with highly tailored screening and prevention strategies that are specifically designed to address their long-term health needs, intervening proactively and effectively.
A notable expansion in WISDOM 2.0 is the inclusion of women as young as 30 years old. This strategic decision reflects the growing understanding that certain inherited genetic variants can significantly increase the risk of aggressive early-onset cancers. By extending enrollment to younger cohorts, researchers aim to identify these individuals earlier in their lives, allowing for timely and intensive surveillance that could be critical in preventing advanced disease. This early identification and intervention align perfectly with the personalized medicine ethos, ensuring that even younger women, who might traditionally be overlooked by age-based guidelines, receive the care appropriate for their unique risk profile.
Since its launch in 2016, the WISDOM study has already enrolled an impressive total of more than 80,000 women, demonstrating the widespread interest and participation in this transformative research. The ongoing commitment to expanding and refining the study through WISDOM 2.0 underscores the long-term vision of its investigators: to continuously advance the science of breast cancer screening and prevention, ultimately creating a future where every woman receives the most effective and personalized care possible. This iterative approach to research promises to keep breast cancer screening at the forefront of medical innovation, ensuring that guidelines and practices remain aligned with the latest scientific understanding.
Collaborations and Funding
The monumental scope and success of the WISDOM study are a testament to the power of collaborative research and robust financial support. The study involved a vast network of investigators and institutions, highlighting the multidisciplinary effort required to tackle such a complex public health challenge.
In addition to the coordinating efforts of UCSF, key investigators and collaborators hail from a wide array of institutions across the United States, including UC Los Angeles, UC Irvine, UC San Diego, San Francisco VA Health Care System, Sanford Health in North Dakota, University of Chicago, Diagnostic Center of Miami, University of Alabama, Virginia Commonwealth University, and Weill Cornell Medicine in New York. The international reach of the collaboration also extended to the Karolinska Institutet in Stockholm, underscoring the global relevance of this research.
The comprehensive list of co-authors from UCSF includes Laura J. van ‘t Veer, PhD; Maren T. Scheuner MD; Alexander D. Borowsky, MD; Amie M. Blanco, MD; Katherine S. Ross, MS; Barry S. Tong, MS; Diane Heditsian; Susie Brain; Vivian Lee; Kelly Blum, MS; Mi-Ok Kim, PhD; Leah P. Sabacan, MBA; Kirkpatrick B. Fergus, MD; Christina Yau, PhD; Celia Kaplan, DrPH; Suzanne Elder, CFNP; Kelly Adduci, MPH; Jeffrey B. Matthews, PhD; Robert A. Hiatt, MD, PhD; Elad Ziv, MD; and Jeffrey A. Tice, MD.
Financial support, crucial for sustaining a study of this magnitude, was provided by several prominent organizations. Key funding sources included the Patient-Centered Outcomes Research Institute (PCORI), the National Cancer Institute (NCI) through grant R01CA237533, and the Breast Cancer Research Foundation (BCRF). Additional funding sources are detailed within the published paper, reflecting the broad investment in this critical area of research.
It is also noted that conflicts of interest were disclosed, ensuring transparency in the research process. Dr. Esserman is a medical advisory panel member for Blue Cross Blue Shield and has received author fees from the UpToDate electronic medical information resource. Further disclosures for other investigators are available in the published paper.
In conclusion, the WISDOM study marks a pivotal moment in the fight against breast cancer. Its findings advocate for a future where screening is not a generalized mandate but a highly personalized, dynamic process, finely tuned to the individual risk of each woman. This shift promises to usher in an era of more effective, safer, and ultimately more humane breast cancer prevention and detection.
About the Author
